Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review

References

• Wilczek A, Sticherling M. Concomitant psoriasis and bullous pemphigoid: coincidence or pathogenic relationship? Int J Dermatol. 2006;45(11):1353–1357.
   PubMed Web of Science ®Google Scholar
• Rao R, Gupta A, Yunis F, et al. Coexistence of psoriasis with bullous pemphigoid. Indian Dermatol Online J. 2012;3(2):119–121.
   PubMedGoogle Scholar
• Barnadas MA, Gilaberte M, Pujol R, et al. Alomar a bullous pemphigoid in a patient with psoriasis during the course of PUVA therapy: study by ELISA test. Int J Dermatol. 2006; Sep45(9):1089–1092.
   PubMed Web of Science ®Google Scholar
• https://www.ncbi.nlm.nih.gov/books/NBK548069/ [cited May 2021].
   Google Scholar
• Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther. 1977;21(3):247–254.
   PubMed Web of Science ®Google Scholar
• Stausbøl-Grøn B, Deleuran M, Sommer Hansen E, et al. Development of bullous pemphigoid during treatment of psoriasis with adalimumab. Clin Exp Dermatol. 2009;34(7):e285–e286.
   PubMed Web of Science ®Google Scholar
• Tirado-Sánchez A, Bonifaz A. Simultaneous bullous pemphigoid and vitiligo associated with adalimumab therapy in a patient with psoriasis vulgaris. Indian Dermatol Online J. 2020;11(2):229–231.
   PubMedGoogle Scholar
• Duong TA, Buffard V, André C, et al. Efalizumab-induced bullous pemphigoid. J Am Acad Dermatol. 2010;62(1):161–162.
   PubMed Web of Science ®Google Scholar
• Monnier-Murina K, Du Thanh A, Merlet-Albran S, et al. Bullous pemphigoid occurring during efalizumab treatment for psoriasis: a paradoxical auto-immune reaction? Dermatology 2009;219(1):89–90.
   PubMed Web of Science ®Google Scholar
• Oberthür F, Baur-Beger S, Wagner A, et al. Occurrence of a bullous pemphigoid with efalizumab therapy in psoriasis vulgaris. Akt Dermatol. 2008;34(01/02):19–21.
   Google Scholar
• BerbertFerreira S, BerbertFerreira R, Costa B, et al. Onset of bullous pemphigoid during psoriasis treatment with etanercept and remission with ustekinumab. J Dermatol Nurses Assoc. 2020;12:2.
   Google Scholar
• Wilmer EN, Becker N, Chen A, et al. Etanercept-induced generalization of chronic, localized, anogenital bullous pemphigoid in a psoriatic patient. JAAD Case Rep. 2016;22(1):25–27.
   Google Scholar
• Kluk J, Goulding JM, Bhat J, et al. Drug-induced bullous pemphigoid: cases triggered by intravenous iodine and etanercept. Clin Exp Dermatol. 2011;36(8):871–873.
   PubMed Web of Science ®Google Scholar
• Marin M, Alzueta N, Castresana M, et al. Bullous pemphigoid induced by ustekinumab: a case report. Eur J Hosp Pharm. 2021;28(1):47–49.
   PubMedGoogle Scholar
• Querol-Cisneros E, Moreno-Artero E, Rodríguez-Garijo N, et al. Bullous pemphigoid without detection of autoantibodies in a patient with psoriasis under ustekinumab. J Dtsch Dermatol Ges. 2021;19(2):265–267.
   Web of Science ®Google Scholar
• Vural S, Gündoğdu M, Ertop P, et al. Ustekinumab associated bullous pemphigoid in a psoriasis patient and a review of the literature. Turkish Arch Dermatol Venereol. 2019;53(1):32–35.
   Web of Science ®Google Scholar
• Onsun N, Sallahoglu K, Dizman D, et al. Bullous pemphigoid during ustekinumab therapy in a psoriatic patient. Eur J Dermatol. 2017;27(1):81–82.
   PubMed Web of Science ®Google Scholar
• Le Guern A, Alkeraye S, Vermersch-Langlin A, et al. Bullous pemphigoid during ustekinumab therapy. JAAD Case Rep. 2015;1(6):359–360.
   PubMedGoogle Scholar
• Nakayama C, Fujita Y, Watanabe M, et al. Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab. J Dermatol. 2015;42(10):996–998.
   PubMed Web of Science ®Google Scholar
• Ho PH, Tsai TF. Development of bullous pemphigoid during secukinumab treatment for psoriasis. J Dermatol. 2017;44(9):e220–e221.
   PubMed Web of Science ®Google Scholar
• Chatzidakis I, Mamalaki CT. Cells as sources and targets of tnf: Implications for immunity and autoimmunity. Curr Dir Autoimmun. 2010;11:105–118.
   PubMedGoogle Scholar
• Ramos-Casals M, Brito-Zerón P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86(4):242–251.
   PubMed Web of Science ®Google Scholar
• De Bandt M, Sibilia J, Le Loët X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7(3):R545–51.
   PubMed Web of Science ®Google Scholar
• D'Auria F, Rovere‐Qerini P, Giazzon M, et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med. 2004;255(3):409–418.
   PubMed Web of Science ®Google Scholar
• Louis M, Rauch J, Armstrong M, et al. Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol. 2003;30(12):2557–2562.
   PubMed Web of Science ®Google Scholar
• Eriksson C, Engstrand S, Sundqvist KG, et al. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005;64(3):403–407.
   PubMed Web of Science ®Google Scholar
• Via CS, Shustov A, Rus V, et al. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol. 2001;167(12):6821–6826.
   PubMed Web of Science ®Google Scholar
• Ferraccioli G, Mecchia F, Di Poi E, et al. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis. 2002;61(4):358–361.
   PubMed Web of Science ®Google Scholar
• Nin M, Tokunaga D, Ishii N, et al. Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept. J Dermatol. 2013;40(1):55–56.
   PubMed Web of Science ®Google Scholar
• Yamauchi PS, Lowe NJ, Gindi V. Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol. 2006;54(3 Suppl 2):S121–S122.
   PubMed Web of Science ®Google Scholar
• Cusano F, Iannazzone SS, Riccio G, et al. Coexisting bullous pemphigoid and psoriasis successfully treated with etanercept. Eur J Dermatol. 2010;20(4):520.
   PubMed Web of Science ®Google Scholar
• Saraceno R, Citarella L, Spallone G, et al. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. Clin Exp Dermatol. 2008;33(2):154–155.
   PubMed Web of Science ®Google Scholar
• Sacher C, Rubbert A, König C, et al. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol. 2002;46(1):113–115.
   Google Scholar
• Canizares MJ, Smith DI, Conners MS, et al. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol. 2006;142(11):1457–1461.
   PubMedGoogle Scholar
• Kowalski EH, Kneibner D, Kridin K, et al. Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Autoimmun Rev. 2019;18(5):526–534.
   PubMed Web of Science ®Google Scholar
• D'Auria L, Mussi A, Bonifati C, et al. Increased serum IL-6, TNF-alpha and IL-10 levels in patients with bullous pemphigoid: relationships with disease activity. J Eur Acad Dermatol Venerol. 1999;12(1):11–15.
   PubMed Web of Science ®Google Scholar
• Liu Z, Dang E, Li B, et al. Dysfunction of CD19 + CD24hiCD27+ B regulatory cells in patients with bullous pemphigoid. Sci Rep. 2018;8(1):703.
   PubMedGoogle Scholar
• Liu LY, Bates ME, Jarjour NN, et al. Generation of Th1 and Th2 chemokines by human eosinophils: evidence for a critical role of TNF-alpha. J Immunol. 2007;179(7):4840–4848.
   PubMed Web of Science ®Google Scholar
• Reddy M, Torres G, McCormick T, et al. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J Dermatol. 2010;37(5):413–425.
   PubMed Web of Science ®Google Scholar
• Loget J, Plée J, Antonicelli F, et al. A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):e228–e230.
   PubMed Web of Science ®Google Scholar
• Majima Y, Yagi H, Tateishi C, et al. A successful treatment with ustekinumab in a case of antilaminin-γ1 pemphigoid associated with psoriasis. Br J Dermatol. 2013;168(6):1367–1369.
   PubMed Web of Science ®Google Scholar
• van Ammers M, Lai FYX, Abrahams T, et al. Bullous pemphigoid in a young male during treatment with adalimumab. Aust J Dermatol. 2021;62(1):e155–e156.
   Web of Science ®Google Scholar
• Sugaya M, Ishii M, Takahashi-Shishido N, et al. Case of bullous pemphigoid under treatment with adalimumab for hidradenitis suppurativa. J Dermatol. 2021.
   Google Scholar
• Bordignon M, Belloni-Fortina A, Pigozzi B, et al. Bullous pemphigoid during long-term TNF-alpha blocker therapy. Dermatology 2009;219(4):357–358.
   PubMed Web of Science ®Google Scholar
• Boussemart L, Jacobelli S, Batteux F, et al. Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports. Dermatology 2010;221(3):201–205.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Ishii T. Analysis of patients with drug-induced pemphigoid using the Japanese adverse drug event report database. J Dermatol. 2019;46(3):240–244.
   PubMed Web of Science ®Google Scholar
• Plée J, Le Jan S, Giustiniani J, et al. Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome. Sci Rep. 2015;5:18001.
   PubMed Web of Science ®Google Scholar
• Chakievska L, Holtsche MM, Künstner A, et al. IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. J Autoimmun. 2019;96:104–112.
   PubMed Web of Science ®Google Scholar
• Nesmond S, Muller C, Le Naour R, et al. Characteristic pattern of IL-17RA, IL-17RB, and IL-17RC in monocytes/macrophages and mast cells from patients with bullous pemphigoid. Front Immunol. 2019;10:2107.
   PubMed Web of Science ®Google Scholar
• Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39–50.
   PubMed Web of Science ®Google Scholar
• Ohata C, Ishii N, Koga H, et al. Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: a series of 145 cases. J Am Acad Dermatol. 2015;73(1):50–55.
   PubMed Web of Science ®Google Scholar
• Kridin K, Ludwig RJ, Schonmann Y, et al. The bidirectional association between bullous pemphigoid and psoriasis: a population-based cohort study. Front Med (Lausanne). 2020;7:511.
   PubMed Web of Science ®Google Scholar
• Dainichi T, Kabashima K. Interaction of psoriasis and bullous diseases. Front Med (Lausanne). 2018;5:222.
   PubMed Web of Science ®Google Scholar
• Kashihara M, Danno K, Miyachi Y, et al. Bullous pemphigoid-like lesions induced by phenacetin. Report of a case and an immunopathologic study. Arch Dermatol. 1984;120(9):1196–1199.
   PubMedGoogle Scholar
• Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol. 2014;28(9):1133–1140.
   PubMed Web of Science ®Google Scholar
• Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol. 2007;33(1-2):67–77.
   PubMed Web of Science ®Google Scholar
• Smith EP, Taylor TB, Meyer LJ, et al. Antigen identification in drug-induced bullous pemphigoid. J Am Acad Dermatol. 1993;29(5 Pt 2):879–882.
   PubMed Web of Science ®Google Scholar
• Kalaaji NE, Nicolas MEO. Linear basement membrane zone staining pattern. In Kalaaji NE, Nicolas MEO eds. Mayo clinic atlas of immunofluorescence in dermatology. Boca Raton (FL): Mayo Clinic Scientific Press; 2006. p. 1–3.
   Google Scholar
• De Jong MC, Bruins S, Heeres K, et al. Bullous pemphigoid and epidermolysis bullosa acquisita. Differentiation by fluorescence overlay antigen mapping. Arch Dermatol. 1996;132(2):151–157.
   PubMedGoogle Scholar
• Lee JJ, Downham T. Furosemide induced bullous pemphigoid: case report and review of literature. J Drugs Dermatol. 2006;5(6):562–564.
   PubMedGoogle Scholar